Pre-Market Analysis on Dendreon, ACADIA Pharma, Medivation, and Cell Therapeutics

     Pre-Market Analysis on Dendreon, ACADIA Pharma, Medivation, and Cell

PR Newswire

LONDON, April 5, 2013

LONDON, April 5, 2013 /PRNewswire/ --

Swiss pharmaceutical major Novartis AG recently lost a patent case related to
its cancer drug in India. The development once again highlights that drug
manufacturers are facing significant competition from generic drugs. Major
pharmaceutical companies have already seen patents on several blockbuster
drugs expire over the last one year. The key for pharma companies will be to
boost their product portfolio through research and development. Pharma
companies can also look to acquire or partner with biotechnology companies
that have developed or are developing potential blockbuster drugs. Dendreon
Corporation (NASDAQ: DNDN), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD),
Medivation Inc. (NASDAQ: MDVN), and Cell Therapeutics Inc. (NASDAQ: CTIC) are
some of the biotechnology companies that could generate interest among major
drug manufacturers. On Thursday, biotechnology stocks ended mostly higher,
tracking gains in the broad market.StockCall has posted free technical
research on DNDN, ACAD, MDVN, and CTIC which can be downloaded upon sign up at

Shares of Dendreon Corporation edged higher on Thursday; however, the gains
were limited. The stock ended the day 0.43% higher at $4.72 on volume of 1.76
million. Dendreon's shares have gained nearly 2.40% in the last three trading
sessions. Year-to-date, the stock is down nearly 10.80%. The company's shares
are currently trading more than 61% below their 52-week high. Shares of DNDN
are currently trading well below their 50-day and 200-day moving averages,
which is a bearish signal. Sign up and read the complimentary report on DNDN

Shares of ACADIA Pharmaceuticals Inc. rose sharply in trading yesterday. The
stock touched an intra-day high of $7.75 before finishing the day 1.32% higher
at $7.69 on volume of 916,412. Despite the gains on Thursday, ACADIA Pharma's
shares have fallen 2.6% in the last three sessions. Year-to-date, however, the
stock is still up more than 65%. ACADIA's shares have seen a pullback after
the stock failed to break through $8.50 resistance level. The stock's MACD
chart is currently giving bearish signals. The free report on ACAD can be
downloaded by signing up now at

Shares of Medivation Inc. rallied in Thursday's trading session. The stock
closed 5.79% higher at $48.75 on above average volume of 2.06 million.
Medivation's shares touched an intra-day high of $49 yesterday. The company's
shares have had an excellent run over the past five trading sessions, gaining
nearly 10%. The stock is now approaching $49 resistance level. The stock's
MACD has crossed above the signal line, which is a bullish signal. Free report
on MDVN can be accessed by registering at

Shares of Cell Therapeutics Inc. fell sharply in trading in its last trading
session. The stock ended the day 1.77% lower at $1.11 on volume of 469,952 on
Thursday. Cell Therapeutics' shares touched an intra-day low of $1.09
yesterday. The stock is currently trading close to its 52-week low of $1.02.
Year-to-date, the stock has fallen more than 14.60%. The company's shares have
seen a series of lows since the start of this year, which is a bearish signal.
The bearish trend is further confirmed by the stock's MACD chart. Shares of
CTIC are also trading below their 50-day and 200-day moving averages. Register
with StockCall and download the research on CTIC for free at

About is a financial website where investors can have easy, precise
and comprehensive research and opinions on stocks making the headlines. Sign
up today to talk to our financial analyst at


Contact: Contact Person: William T. Knight, Email:, Contact
Number: +1-(646)396-9857 (9:00 am EST - 01:30 pm EST)
Press spacebar to pause and continue. Press esc to stop.